Helicobacter pylori and malignant lymphoma in Spain

S. de Sanjose, A. Dickie, T. Alvaro, V. Romagosa, M. Garcia Villanueva, E. Domingo-Domenech, A. Fernandez de Sevilla, Emad Munir El-Omar

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Helicobacter pylori has been associated with gastric adenocarcinoma and gastric lymphoma. We report on the systematic evaluation of serologic detection of H. pylori in a lymphoma case-control study. Methods: Cases (N = 536) were consecutive patients newly diagnosed with a lymphoid malignancy between 1998 and 2002 in four centers in Spain. Lymphomas were diagnosed and classified using the WHO Classification. Controls (N = 603) were hospitalized patients frequency-matched to the cases by 5-year age group, sex, and study center. Severe immunocompromised patients were excluded as controls. Patients underwent a personal interview and blood sampling. H. pylori infection was evaluated by the presence of IgG antibodies using the Premier enzyme immunoassay kit (Meridian Diagnostics Inc., Cincinnati, OH). Logistic regression analysis was used to estimate the odds ratios and 95% confidence intervals (OR, 95% Cl) for lymphoma categories. Results: Anti-H. pylori antibodies were detected in 68.5% of the cases and 71.3% of the controls (P = 0.29) H. pylori was associated with a 3-fold excess risk of splenic marginal B-cell lymphoma (OR = 3.97, 95% Cl = 0.92-17.16). H. pylori was not associated with an overall increased risk of extranodal lymphomas (OR = 0.73, 95% Cl = 0.44-1.22) but when specific sites were explored, the four mucosa-associated lymphoid tissue and the six diffuse large B-cell lymphomas primary localized in the stomach were all H. pylori seropositive. Conclusion: Persistent infection with H. pylori may be implicated in the development of lymphomas of the gastric mucosa and of the spleen. These results could have clinical implications in the management of splenic marginal zone lymphomas.

Original languageEnglish
Pages (from-to)944-948
Number of pages4
JournalCancer Epidemiology, Biomarkers and Prevention
Volume13
Issue number6
Publication statusPublished - 2004

Keywords

  • splenic marginal zone
  • B-cell lymphomas
  • gastric malt lymphoma
  • alcohol-consumption
  • pancreatic-cancer
  • virus-infection
  • tissue type
  • association
  • eradication
  • specificity

Cite this

de Sanjose, S., Dickie, A., Alvaro, T., Romagosa, V., Garcia Villanueva, M., Domingo-Domenech, E., ... El-Omar, E. M. (2004). Helicobacter pylori and malignant lymphoma in Spain. Cancer Epidemiology, Biomarkers and Prevention, 13(6), 944-948.

Helicobacter pylori and malignant lymphoma in Spain. / de Sanjose, S.; Dickie, A.; Alvaro, T.; Romagosa, V.; Garcia Villanueva, M.; Domingo-Domenech, E.; Fernandez de Sevilla, A.; El-Omar, Emad Munir.

In: Cancer Epidemiology, Biomarkers and Prevention, Vol. 13, No. 6, 2004, p. 944-948.

Research output: Contribution to journalArticle

de Sanjose, S, Dickie, A, Alvaro, T, Romagosa, V, Garcia Villanueva, M, Domingo-Domenech, E, Fernandez de Sevilla, A & El-Omar, EM 2004, 'Helicobacter pylori and malignant lymphoma in Spain', Cancer Epidemiology, Biomarkers and Prevention, vol. 13, no. 6, pp. 944-948.
de Sanjose S, Dickie A, Alvaro T, Romagosa V, Garcia Villanueva M, Domingo-Domenech E et al. Helicobacter pylori and malignant lymphoma in Spain. Cancer Epidemiology, Biomarkers and Prevention. 2004;13(6):944-948.
de Sanjose, S. ; Dickie, A. ; Alvaro, T. ; Romagosa, V. ; Garcia Villanueva, M. ; Domingo-Domenech, E. ; Fernandez de Sevilla, A. ; El-Omar, Emad Munir. / Helicobacter pylori and malignant lymphoma in Spain. In: Cancer Epidemiology, Biomarkers and Prevention. 2004 ; Vol. 13, No. 6. pp. 944-948.
@article{5b18fc7d4f7e4383991058ca29bc4045,
title = "Helicobacter pylori and malignant lymphoma in Spain",
abstract = "Helicobacter pylori has been associated with gastric adenocarcinoma and gastric lymphoma. We report on the systematic evaluation of serologic detection of H. pylori in a lymphoma case-control study. Methods: Cases (N = 536) were consecutive patients newly diagnosed with a lymphoid malignancy between 1998 and 2002 in four centers in Spain. Lymphomas were diagnosed and classified using the WHO Classification. Controls (N = 603) were hospitalized patients frequency-matched to the cases by 5-year age group, sex, and study center. Severe immunocompromised patients were excluded as controls. Patients underwent a personal interview and blood sampling. H. pylori infection was evaluated by the presence of IgG antibodies using the Premier enzyme immunoassay kit (Meridian Diagnostics Inc., Cincinnati, OH). Logistic regression analysis was used to estimate the odds ratios and 95{\%} confidence intervals (OR, 95{\%} Cl) for lymphoma categories. Results: Anti-H. pylori antibodies were detected in 68.5{\%} of the cases and 71.3{\%} of the controls (P = 0.29) H. pylori was associated with a 3-fold excess risk of splenic marginal B-cell lymphoma (OR = 3.97, 95{\%} Cl = 0.92-17.16). H. pylori was not associated with an overall increased risk of extranodal lymphomas (OR = 0.73, 95{\%} Cl = 0.44-1.22) but when specific sites were explored, the four mucosa-associated lymphoid tissue and the six diffuse large B-cell lymphomas primary localized in the stomach were all H. pylori seropositive. Conclusion: Persistent infection with H. pylori may be implicated in the development of lymphomas of the gastric mucosa and of the spleen. These results could have clinical implications in the management of splenic marginal zone lymphomas.",
keywords = "splenic marginal zone, B-cell lymphomas, gastric malt lymphoma, alcohol-consumption, pancreatic-cancer, virus-infection, tissue type, association, eradication, specificity",
author = "{de Sanjose}, S. and A. Dickie and T. Alvaro and V. Romagosa and {Garcia Villanueva}, M. and E. Domingo-Domenech and {Fernandez de Sevilla}, A. and El-Omar, {Emad Munir}",
year = "2004",
language = "English",
volume = "13",
pages = "944--948",
journal = "Cancer Epidemiology, Biomarkers and Prevention",
issn = "1055-9965",
publisher = "AMER ASSOC CANCER RESEARCH",
number = "6",

}

TY - JOUR

T1 - Helicobacter pylori and malignant lymphoma in Spain

AU - de Sanjose, S.

AU - Dickie, A.

AU - Alvaro, T.

AU - Romagosa, V.

AU - Garcia Villanueva, M.

AU - Domingo-Domenech, E.

AU - Fernandez de Sevilla, A.

AU - El-Omar, Emad Munir

PY - 2004

Y1 - 2004

N2 - Helicobacter pylori has been associated with gastric adenocarcinoma and gastric lymphoma. We report on the systematic evaluation of serologic detection of H. pylori in a lymphoma case-control study. Methods: Cases (N = 536) were consecutive patients newly diagnosed with a lymphoid malignancy between 1998 and 2002 in four centers in Spain. Lymphomas were diagnosed and classified using the WHO Classification. Controls (N = 603) were hospitalized patients frequency-matched to the cases by 5-year age group, sex, and study center. Severe immunocompromised patients were excluded as controls. Patients underwent a personal interview and blood sampling. H. pylori infection was evaluated by the presence of IgG antibodies using the Premier enzyme immunoassay kit (Meridian Diagnostics Inc., Cincinnati, OH). Logistic regression analysis was used to estimate the odds ratios and 95% confidence intervals (OR, 95% Cl) for lymphoma categories. Results: Anti-H. pylori antibodies were detected in 68.5% of the cases and 71.3% of the controls (P = 0.29) H. pylori was associated with a 3-fold excess risk of splenic marginal B-cell lymphoma (OR = 3.97, 95% Cl = 0.92-17.16). H. pylori was not associated with an overall increased risk of extranodal lymphomas (OR = 0.73, 95% Cl = 0.44-1.22) but when specific sites were explored, the four mucosa-associated lymphoid tissue and the six diffuse large B-cell lymphomas primary localized in the stomach were all H. pylori seropositive. Conclusion: Persistent infection with H. pylori may be implicated in the development of lymphomas of the gastric mucosa and of the spleen. These results could have clinical implications in the management of splenic marginal zone lymphomas.

AB - Helicobacter pylori has been associated with gastric adenocarcinoma and gastric lymphoma. We report on the systematic evaluation of serologic detection of H. pylori in a lymphoma case-control study. Methods: Cases (N = 536) were consecutive patients newly diagnosed with a lymphoid malignancy between 1998 and 2002 in four centers in Spain. Lymphomas were diagnosed and classified using the WHO Classification. Controls (N = 603) were hospitalized patients frequency-matched to the cases by 5-year age group, sex, and study center. Severe immunocompromised patients were excluded as controls. Patients underwent a personal interview and blood sampling. H. pylori infection was evaluated by the presence of IgG antibodies using the Premier enzyme immunoassay kit (Meridian Diagnostics Inc., Cincinnati, OH). Logistic regression analysis was used to estimate the odds ratios and 95% confidence intervals (OR, 95% Cl) for lymphoma categories. Results: Anti-H. pylori antibodies were detected in 68.5% of the cases and 71.3% of the controls (P = 0.29) H. pylori was associated with a 3-fold excess risk of splenic marginal B-cell lymphoma (OR = 3.97, 95% Cl = 0.92-17.16). H. pylori was not associated with an overall increased risk of extranodal lymphomas (OR = 0.73, 95% Cl = 0.44-1.22) but when specific sites were explored, the four mucosa-associated lymphoid tissue and the six diffuse large B-cell lymphomas primary localized in the stomach were all H. pylori seropositive. Conclusion: Persistent infection with H. pylori may be implicated in the development of lymphomas of the gastric mucosa and of the spleen. These results could have clinical implications in the management of splenic marginal zone lymphomas.

KW - splenic marginal zone

KW - B-cell lymphomas

KW - gastric malt lymphoma

KW - alcohol-consumption

KW - pancreatic-cancer

KW - virus-infection

KW - tissue type

KW - association

KW - eradication

KW - specificity

M3 - Article

VL - 13

SP - 944

EP - 948

JO - Cancer Epidemiology, Biomarkers and Prevention

JF - Cancer Epidemiology, Biomarkers and Prevention

SN - 1055-9965

IS - 6

ER -